Targeting of tumor growth and angiogenesis underlies the enhanced antitumor activity of lenvatinib in combination with everolimus

The combination of lenvatinib, a multiple receptor tyrosine kinase inhibitor, plus everolimus, a mammalian target of rapamycin (mTOR) inhibitor, significantly improved clinical outcomes versus everolimus monotherapy in a phase II clinical study of metastatic renal cell carcinoma (RCC). We investigat...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancer Sci
Autori principali: Matsuki, Masahiro, Adachi, Yusuke, Ozawa, Yoichi, Kimura, Takayuki, Hoshi, Taisuke, Okamoto, Kiyoshi, Tohyama, Osamu, Mitsuhashi, Kaoru, Yamaguchi, Atsumi, Matsui, Junji, Funahashi, Yasuhiro
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley and Sons Inc. 2017
Soggetti:
Original Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5406533/
https://ncbi.nlm.nih.gov/pubmed/28107584
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13169
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi